For graft failure, hypercholesterolemia was significantly associated with increased risk in recipients without mTOR therapy (HR 1.85, 95% CI 1.17–2.90, p = 0.01), while it showed a marginally insignificant association with decreased risk of graft failure in recipients with mTOR therapy (HR 0.49, 95% CI 0.19–1.26, p = 0.14), and the interaction had a p-value = 0.01. Here, MTOR is linked to familial hypercholesterolemia.